- Home
- SLN vs REX Comparison
SLN vs REX Comparison
Compare SLN & REX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- REX
- Stock Information
- Founded
- SLN 1994
- REX 1980
- Country
- SLN United Kingdom
- REX United States
- Employees
- SLN N/A
- REX N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- REX Major Chemicals
- Sector
- SLN Health Care
- REX Industrials
- Exchange
- SLN Nasdaq
- REX Nasdaq
- Market Cap
- SLN 919.6M
- REX 803.1M
- IPO Year
- SLN N/A
- REX N/A
- Fundamental
- Price
- SLN $18.50
- REX $46.54
- Analyst Decision
- SLN Strong Buy
- REX Strong Buy
- Analyst Count
- SLN 4
- REX 1
- Target Price
- SLN $61.50
- REX $60.00
- AVG Volume (30 Days)
- SLN 179.3K
- REX 129.7K
- Earning Date
- SLN 11-12-2024
- REX 11-29-2024
- Dividend Yield
- SLN N/A
- REX N/A
- EPS Growth
- SLN N/A
- REX 166.93
- EPS
- SLN N/A
- REX 3.92
- Revenue
- SLN $22,623,125.00
- REX $718,079,000.00
- Revenue This Year
- SLN N/A
- REX N/A
- Revenue Next Year
- SLN $104.98
- REX $13.53
- P/E Ratio
- SLN N/A
- REX $11.96
- Revenue Growth
- SLN N/A
- REX N/A
- 52 Week Low
- SLN $6.51
- REX $35.73
- 52 Week High
- SLN $27.72
- REX $60.79
- Technical
- Relative Strength Index (RSI)
- SLN 48.92
- REX 55.31
- Support Level
- SLN $18.20
- REX $44.34
- Resistance Level
- SLN $19.36
- REX $46.93
- Average True Range (ATR)
- SLN 0.88
- REX 1.29
- MACD
- SLN -0.04
- REX 0.03
- Stochastic Oscillator
- SLN 35.50
- REX 81.18
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.